IOM Committee Questions Adequacy Of Compliance Tools In 510(k) Program
This article was originally published in The Gray Sheet
Executive Summary
Questions about the adequacy of FDA's compliance and surveillance tools for 510(k) products were among those raised by an Institute of Medicine task force during its second public meeting to evaluate the pre-market clearance program
You may also be interested in...
Broad 510(k) Reform Still On The Table; IOM Panel Enters Closed-Door Phase
The Institute of Medicine committee charged with recommending reforms to FDA's 510(k) clearance program will move the remainder of its efforts behind closed doors
Broad 510(k) Reform Still On The Table; IOM Panel Enters Closed-Door Phase
The Institute of Medicine committee charged with recommending reforms to FDA's 510(k) clearance program will move the remainder of its efforts behind closed doors
CDRH Pre-Market Reform Proposals Expected Within Weeks
The FDA device center's upcoming proposals for reforming its pre-market policies will directly address widespread industry concern that reviews are increasingly unpredictable and opaque, CDRH Director Jeff Shuren told an industry audience last week